Rapport Therapeutics (RAPP) holders elect Class II board, ratify PwC
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Rapport Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders voted on board elections and auditor ratification. As of the April 14, 2026 record date, 47,807,623 shares of common stock were outstanding and entitled to vote.
Stockholders elected three Class II directors to serve until the 2029 annual meeting: James Healy, M.D., Ph.D. (41,762,713 votes for and 587,163 withheld), Robert J. Perez (37,592,089 for and 4,757,787 withheld), and Raymond Sanchez, M.D. (41,754,131 for and 595,745 withheld), each with 1,983,035 broker non-votes. Shareholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026, with 44,255,547 votes for, 57,445 against, and 19,919 abstentions.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares entitled to vote: 47,807,623 shares
Votes for James Healy: 41,762,713 votes
Votes for Robert J. Perez: 37,592,089 votes
+4 more
7 metrics
Shares entitled to vote
47,807,623 shares
Common stock outstanding as of April 14, 2026 record date
Votes for James Healy
41,762,713 votes
Election as Class II director at 2026 annual meeting
Votes for Robert J. Perez
37,592,089 votes
Election as Class II director at 2026 annual meeting
Votes for Raymond Sanchez
41,754,131 votes
Election as Class II director at 2026 annual meeting
Broker non-votes per director
1,983,035 votes
Broker non-votes on each Class II director proposal
Votes for PwC ratification
44,255,547 votes
Ratification of PwC as independent auditor for 2026
Votes against PwC ratification
57,445 votes
Opposing PwC as independent auditor for 2026
Key Terms
Annual Meeting of Stockholders, record date, Class II directors, independent registered public accounting firm, +2 more
6 terms
Annual Meeting of Stockholders financial
"held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)."
record date financial
"As of the close of business on April 14, 2026, the record date for the Annual Meeting"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
Class II directors financial
"to elect James Healy, M.D., Ph.D., Robert J. Perez, and Raymond Sanchez, M.D. as Class II directors of the Company"
independent registered public accounting firm financial
"to ratify the appointment of PricewaterhouseCoopers LLP (“PwC”) as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
broker non-votes financial
"James Healy, M.D., Ph.D. | | 41,762,713 | | 587,163 | | 1,983,035"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
emerging growth company financial
"Emerging growth company Item 5.07 Submission of Matters to a Vote of Security Holders."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
Were the director nominees elected at Rapport Therapeutics’ 2026 annual meeting?
Yes, all three Class II director nominees were elected. James Healy, Robert J. Perez, and Raymond Sanchez each received more votes “for” than “withheld,” and will serve until the 2029 annual meeting or until a successor is duly elected and qualified.
What were the vote results for Rapport Therapeutics’ auditor ratification in 2026?
Shareholders strongly supported ratifying PricewaterhouseCoopers LLP as independent registered public accounting firm, with 44,255,547 votes for, 57,445 against, and 19,919 abstentions. This confirms PwC for the audit of the fiscal year ending December 31, 2026.
What are broker non-votes in Rapport Therapeutics’ 2026 director elections?
Broker non-votes are shares held in street name where the broker did not receive voting instructions on non-routine matters. For each Class II director, there were 1,983,035 broker non-votes, which are counted for quorum but not as “for” or “against.”
How long will the newly elected Rapport Therapeutics Class II directors serve?
The Class II directors elected in 2026 will serve until the 2029 annual meeting of stockholders. Each will continue until a successor is duly elected and qualified, or until earlier death, resignation, or removal under the company’s governance framework.